LifePoint Hospitals price target raised to $89 from $63 at RBC Capital RBC Capital increased its price target on LifePoint after the company reported beat and raise results that the firm thinks were impressive. The firm, which believes that the beat and raise was largely driven by the ACA, is now more upbeat on the company's visibility and ability to benefit from the ACA. It keeps an Outperform rating on the stock.
LifePoint Hospitals upgraded at RW Baird As previously reported, Baird upgraded LifePoint to Outperform from Neutral. The firm upgraded shares based on valuation, M&A pipeline momentum, improved core operations, and potential further ACA benefit. Price target raised to $76 from $70.